Compelling evidence shows that progestins regulate breast cancer growth. Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level of progesterone receptor isoform A (PR-A) is higher than that of isoform B (PR-B) and that they might stimulate growth when PR-B is predominant. The aims of this study were to investigate ex vivo responses to mifepristone (MFP) in breast carcinomas with different PR isoform ratios and to examine their clinical and molecular characteristics.
Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción:
Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Citación:Rojas, Paola Andrea; May, Maria; Sequeira, Gonzalo Ricardo; Elia, Andres Maximiliano; Alvarez, Michelle; et al.; Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness; Oxford Univ Press Inc; Journal Of The National Cancer Institute.; 109; 7; 7-2017; 1-9